Tazarotene Cream 0.1%

DRUG6 trials

Sponsors

University of Utah, Allergan, Sun Pharmaceutical Industries, Inc., Fougera Pharmaceuticals Inc., Assiut University

Conditions

Acne VulgarisCancerLentigo MalignaNail Psoriasis

Phase 1

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

CompletedNCT02218034

AllerganAcne Vulgaris

Start: 2014-08-31End: 2015-03-31Updated: 2015-04-30

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

CompletedNCT02411955

Sun Pharmaceutical Industries, Inc.Acne Vulgaris

Start: 2014-06-30End: 2015-02-28Updated: 2017-05-04

Phase 3

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

CompletedNCT02886715

Fougera Pharmaceuticals Inc.Acne Vulgaris

Start: 2016-09-21End: 2017-05-31Updated: 2018-08-17

Phase 4

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

TerminatedNCT00829049

AllerganAcne Vulgaris

Start: 2007-10-31End: 2008-10-31Updated: 2012-09-12

Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease

Assiut UniversityNail Psoriasis

Start: 2017-10-01End: 2018-11-01Target: 30Updated: 2017-08-28

Unknown Phase

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

CompletedNCT00707174

University of UtahCancer, Lentigo Maligna

Start: 2005-03-31End: 2013-03-31Updated: 2013-07-31